Systematic (IUPAC) name
(S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate
Clinical data
Legal status
CAS Registry Number
Chemical data
Formula C19H26FN3O3
Molecular mass 363.4 g/mol

5F-AMB (also known as 5F-AMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family,[1] which has been used as an active ingredient in synthetic cannabis products. It was first identified in Japan in early 2014.[2][3] Although there is no pharmacological information about 5F-AMB itself, its 4-cyanobutyl analogue (instead of pentyl) has been reported to be a potent agonist for the CB1 receptor (Ki = 0.7 nM).[4]


  • Side effects 1
  • Legality 2
  • See also 3
  • References 4

Side effects

5F-AMB intoxication caused one fatality through ketoacidosis in combination with AB-CHMINACA, AB-FUBINACA, AM-2201, 5F-APINACA, EAM-2201, JWH-018, JWH-122, MAM-2201, STS-135 and THJ-2201 and another fatality in combination with AB-CHMINACA and Diphenidine.[5][6]


5F-AMB is listed in Anlage II and therefore illegal in Germany as of May 2015.[7]

Sweden's public health agency suggested classifying 5F-AMB as hazardous substance on November 10, 2014.[8]

The state of Louisiana banned 5F-AMB through an emergency rule after it was detected in a synthetic cannabis product called "Kali Berry 2" on 3 June, 2014.[9]

5F-AMB is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[10]

5F-AMB was also scheduled in Japan on July 25, 2014.[11]

As of October 2015 5F-AMB is a controlled substance in China.[12]

See also


  1. ^ "5-Fluoro-AMB". Cayman Chemical. Retrieved 22 June 2015. 
  2. ^ Nahoko Uchiyama, Yoshihiko Shimokawa, Maiko Kawamura, Ruri Kikura-Hanajiri, Takashi Hakamatsuka (August 2014). "Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products". Forensic Toxicology 32 (2): 266–281.  
  3. ^ Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT (Apr 2015). "Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group". Analytical and Bioanalytical Chemistry.  
  4. ^ Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106980
  5. ^ C. Hess, S. Stockhausen, G. Kernbach-Wighton, B. Madea (August 2015). "Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids?". Forensic Science International.  
  6. ^ Koutaro Hasegawa, Amin Wurita, Kayoko Minakata, Kunio Gonmori, Hideki Nozawa, Itaru Yamagishi, Kanako Watanabe, Osamu Suzuki (January 2015). "Postmortem distribution of AB-CHMINACA, 5-fluoro-AMB, and diphenidine in body fluids and solid tissues in a fatal poisoning case: usefulness of adipose tissue for detection of the drugs in unchanged forms". Forensic Toxicology 33 (1): 45–53.  
  7. ^ "Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel)". Retrieved 22 June 2015. 
  8. ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara". Folkhälsomyndigheten. Retrieved 29 June 2015. 
  9. ^ "DHH Adds Two New Synthetic Marijuana Compounds to Banned List". Louisiana Department of Health and Hospitals. 3 June 2014. Retrieved 22 July 2015. 
  10. ^ "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Retrieved 24 July 2015. 
  11. ^ http://npsdb.nihs.go.jp/Search/Default_e.aspx
  12. ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.